Cargando…

Vitamin D-Related Genetics as Predictive Biomarker of Clinical Remission in Adalimumab-Treated Patients Affected by Crohn’s Disease: A Pilot Study

Adalimumab (ADA) is a human anti-tumor necrosis factor (TNF-α) monoclonal antibody used in inflammatory bowel diseases, such as Crohn’s disease (CD). Vitamin-D (VD) is important for biological functions, such as the modulation of expression of genes encoding enzymes and transporters involved in drug...

Descripción completa

Detalles Bibliográficos
Autores principales:	Cusato, Jessica, Bertani, Lorenzo, Antonucci, Miriam, Tomasello, Cristina, Caviglia, Gian Paolo, Dibitetto, Simone, Massano, Alessandro, Mangia, Michela, Mula, Jacopo, Ceccarelli, Linda, Costa, Francesco, Zanzi, Federico, Astegiano, Marco, Ribaldone, Davide Giuseppe, D’Avolio, Antonio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8706953/ https://www.ncbi.nlm.nih.gov/pubmed/34959633 http://dx.doi.org/10.3390/ph14121230

Ejemplares similares

Adalimumab Therapy Improves Intestinal Dysbiosis in Crohn’s Disease
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2019)

Switching from Biosimilar to Biosimilar Adalimumab, Including Multiple Switching, in Crohn’s Disease: A Prospective Study
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2021)

Possible Impact of Vitamin D Status and Supplementation on SARS-CoV-2 Infection Risk and COVID-19 Symptoms in a Cohort of Patients with Inflammatory Bowel Disease
por: De Nicolò, Amedeo, et al.
Publicado: (2022)

Antiretroviral Levels in the Cerebrospinal Fluid: The Effect of Inflammation and Genetic Variants
por: Cusato, Jessica, et al.
Publicado: (2023)

The Usefulness of Microencapsulated Sodium Butyrate Add-On Therapy in Maintaining Remission in Patients with Ulcerative Colitis: A Prospective Observational Study
por: Vernero, Marta, et al.
Publicado: (2020)

Predictive Factors of Surgical Recurrence in Patients with Crohn’s Disease on Long-Term Follow-Up: A Focus on Histology
por: Caviglia, Gian Paolo, et al.
Publicado: (2022)

Factors Influencing the Intracellular Concentrations of the Sofosbuvir Metabolite GS-331007 (in PBMCs) at 30 Days of Therapy
por: Cusato, Jessica, et al.
Publicado: (2022)

Seasonal Variation of Antiretroviral Drug Exposure during the Year: The Experience of 10 Years of Therapeutic Drug Monitoring
por: Cusato, Jessica, et al.
Publicado: (2021)

Stability Study of Fosfomycin in Elastomeric Pumps at 4 °C and 34 °C: Technical Bases for a Continuous Infusion Use for Outpatient Parenteral Antibiotic Therapy
por: Manca, Alessandra, et al.
Publicado: (2023)

Analytical Validation and Clinical Application of Rapid Serological Tests for SARS-CoV-2 Suitable for Large-Scale Screening
por: De Nicolò, Amedeo, et al.
Publicado: (2021)

Long-Term Pharmacokinetics of Dalbavancin in ABSSSI and Osteoarticular Settings: A Real-Life Outpatient Context
por: De Nicolò, Amedeo, et al.
Publicado: (2021)

Antifungal Drug Plasma Exposures: A Possible Contribution of Vitamin D-Related Gene Variants
por: Cusato, Jessica, et al.
Publicado: (2022)

COVID-19: Focusing on the Link between Inflammation, Vitamin D, MAPK Pathway and Oxidative Stress Genetics
por: Cusato, Jessica, et al.
Publicado: (2023)

Oral Manifestations of Inflammatory Bowel Disease and the Role of Non-Invasive Surrogate Markers of Disease Activity
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2020)

Determination of lower cut‐off levels of adalimumab associated with biochemical remission in Crohn's disease
por: Carlsen, Arne, et al.
Publicado: (2019)

Adalimumab for induction of remission in patients with Crohn's disease: a systematic review and meta-analysis
por: Yin, Juntao, et al.
Publicado: (2022)

Adalimumab in Crohn’s disease
por: Van Assche, Gert, et al.
Publicado: (2007)

Shared microbiological and immunological patterns in periodontitis and IBD: A scoping review
por: Baima, Giacomo, et al.
Publicado: (2021)

Long-Term Clinical Remission in Biologically Naïve Crohn's Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
por: Mizoshita, Tsutomu, et al.
Publicado: (2016)

Adalimumab induction and maintenance therapy achieve clinical remission and response in Chinese patients with Crohn's disease
por: Wu, Kai-Chun, et al.
Publicado: (2016)

Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases
por: Bertani, Lorenzo, et al.
Publicado: (2020)

Correlation between Thiopurine S-Methyltransferase Genotype and Adverse Events in Inflammatory Bowel Disease Patients
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2019)

Adalimumab for the treatment of Crohn’s disease
por: Cassinotti, Andrea, et al.
Publicado: (2008)

COVID-19: A Possible Contribution of the MAPK Pathway
por: Cusato, Jessica, et al.
Publicado: (2023)

Adalimumab maintains remission of Crohn's disease after up to 4 years of treatment: data from CHARM and ADHERE
por: Panaccione, R, et al.
Publicado: (2013)

Post-Induction High Adalimumab Drug Levels Predict Biological Remission at Week 24 in Patients With Crohn's Disease
por: Zittan, Eran, et al.
Publicado: (2021)

Incidence of Prostate Cancer in Inflammatory Bowel Disease: A Meta-Analysis
por: Carli, Edoardo, et al.
Publicado: (2020)

On-Treatment Decrease of Serum Interleukin-6 as a Predictor of Clinical Response to Biologic Therapy in Patients with Inflammatory Bowel Diseases
por: Caviglia, Gian Paolo, et al.
Publicado: (2020)

Microscopic colitis in patients with mild duodenal damage: A new clinical and pathological entity (“lymphocytic enterocolitis”)?
por: Bonagura, Gabriele Antonio, et al.
Publicado: (2016)

Risk Factors of Urothelial Cancer in Inflammatory Bowel Disease
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

Adalimumab for the treatment of fistulas in patients with Crohn’s disease
por: Colombel, J-F, et al.
Publicado: (2009)

Management of Crohn’s disease in poor responders to adalimumab
por: de Boer, Nanne KH, et al.
Publicado: (2014)

Efficacy of Adalimumab in Korean Patients with Crohn’s Disease
por: Sohn, Il Woong, et al.
Publicado: (2016)

The Effect of Early vs Delayed Initiation of Adalimumab on Remission Rates in Patients With Crohn’s Disease With Poor Prognostic Factors: The MODIFY Study
por: Mantzaris, Gerassimos J, et al.
Publicado: (2021)

Cost-Effectiveness Analysis of Increased Adalimumab Dose Intervals in Crohn’s Disease Patients in Stable Remission: The Randomized Controlled LADI Trial
por: Jansen, Fenna M, et al.
Publicado: (2023)

Special Issue “Advances in Gastrointestinal and Liver Disease: From Physiological Mechanisms to Clinical Practice”
por: Caviglia, Gian Paolo, et al.
Publicado: (2022)

Efficacy of a Preparation Based on Calcium Butyrate, Bifidobacterium bifidum, Bifidobacterium lactis, and Fructooligosaccharides in the Prevention of Relapse in Ulcerative Colitis: A Prospective Observational Study
por: Caviglia, Gian Paolo, et al.
Publicado: (2021)

Inflammatory Bowel Disease Nurse—Practical Messages
por: Rosso, Chiara, et al.
Publicado: (2021)

Clinical Effectiveness and Pharmacokinetics of Dalbavancin in Treatment-Experienced Patients with Skin, Osteoarticular, or Vascular Infections
por: Stroffolini, Giacomo, et al.
Publicado: (2022)

Comment #2 on “First-Line Helicobacter pylori Eradication with Vonoprazan, Clarithromycin, and Metronidazole in Patients Allergic to Penicillin”
por: Ribaldone, Davide Giuseppe, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_v3et5u8acc5h35uj4tuk368rf0